other material
confidence high
sentiment positive
materiality 0.50
Cocrystal Pharma announces discovery of pan-viral inhibitors with <50 nM potency against hantavirus
Cocrystal Pharma, Inc.
- Novel pan-viral inhibitors target L-protein of Andes hantavirus; IC50 <50 nM against hantaan virus in vitro.
- Company expanding platform from CDI-988 (Phase 1b norovirus) to hantavirus, bunyavirus, influenza.
- No approved treatments or vaccines for hantaviruses; Andes strain linked to recent cruise ship outbreak with 3 deaths.
- Plans to evaluate activity against Andes hantavirus replication enzyme and explore partnerships.